SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001654954-20-004651
Filing Date
2020-04-29
Accepted
2020-04-29 17:19:18
Documents
10
Period of Report
2020-06-26
Effectiveness Date
2020-04-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A cbmg_def14a.htm DEF 14A 894506
2 IMAGE cbmg_def14a000.jpg GRAPHIC 4142
3 IMAGE cbmg_def14a001.jpg GRAPHIC 2769
4 IMAGE cbmg_def14a003.jpg GRAPHIC 11820
5 IMAGE cbmg_def14a007.jpg GRAPHIC 60467
6 IMAGE img001.jpg GRAPHIC 2994
7 IMAGE img002.jpg GRAPHIC 1222
8 IMAGE img003.jpg GRAPHIC 1145
9 IMAGE img004.jpg GRAPHIC 1380
10 IMAGE img005.jpg GRAPHIC 1543
  Complete submission text file 0001654954-20-004651.txt   1017428
Mailing Address 1345 AVENUE OF THE AMERICAS 11TH FLOOR NEW YORK NY 10105
Business Address 1345 AVENUE OF THE AMERICAS 11TH FLOOR NEW YORK NY 10105 (347) 905 5663
Cellular Biomedicine Group, Inc. (Filer) CIK: 0001378624 (see all company filings)

IRS No.: 861032927 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36498 | Film No.: 20831744
SIC: 2836 Biological Products, (No Diagnostic Substances)